

Nerivio® remote electrical neuromodulation (REN) for acute treatment of chronic migraine

Nerivio – a wearable device worn on the upper arm and controlled by a smartphone app

Authors: Hida Nierenburg & Alit Stark-Inbar

Citation: www.futuremedicine.com/doi/10.2217/PMT-2021-0038

Journal: Pain Management



Clinical trials AND real-world evidence

REN mechanism of action (conditioned pain modulation, CPM)



Non-invasive



Non-addictive




Non-pharmacological



Treatment for episodic and chronic migraine



Authorized from age 12 years and above



Treatment for **acute** migraine attacks (i.e. at the time of a migraine attack)



Headache



Phonophobia



Photophobia



Nausea

FDA authorised AND endorsed by the American Headache Society



High efficacy

Over studies: 2/3 of patients experience pain relief and 1/3 of patients experience pain freedom 2 hours after treatment

Effects are sustained over time (24-48 hours)

High safety (Low adverse events)

Minimal side effects, local, transient, and mild

Side effects

Skin redness, warm sensation and itching